超21亿美元!国产BCMA/CD19双靶CAR-T授权出海

生物制品圈
Jul 22, 2025

7月22日,科弈药业宣布,与美国生物医药企业ERIGEN LLC达成战略合作,双方签署了关于科弈药业自主研发的全球首个并联增强型双靶向CAR-T细胞治疗产品KQ-2003(靶向BCMA/CD19)的独家海外授权许可协议。KQ-2003是科弈药业基于增强型双靶CAR-T平台开发的创新疗法,通过并联结构设计和信号域优化,显著提升CAR-T细胞的持久性与抗肿瘤活性,同时降低传统CAR-T的复发风险。根据...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10